Global Enzyme-Linked Immunosorbent Assay (ELISA) Market Size, Share, Opportunities, And Trends By Types (Indirect ELISA, Sandwich ELISA, Competitive ELISA), By Application (Food And Beverage, Vaccine Development, Immunology, Diagnosis, Drug Monitoring, Others), By End Users (Pharmaceutical Industries, Hospitals And Clinics, Diagnostic Centres, Others), And By Geography - Forecasts From 2024 To 2029

The global Enzyme-Linked Immunosorbent Assay (ELISA) market is projected to grow at a CAGR of 4.98% increasing from US$8.884 billion in 2022 to US$12.488 billion in 2029.

ELISA (enzyme-linked immunosorbent assay) or enzyme immunoassay (EIA) is a plate-based assay technique designed for detecting and quantifying substances such as peptides, proteins, antibodies, and hormones. ELISA is often used as a screening tool before further in-depth tests are ordered. Reactants of the ELISA are immobilized to the microplate surface, making it easy to separate bound from non-bound material during the assay. This makes it a powerful tool for measuring specific analytes within a crude preparation.

The common diagnostic applications of ELISA are HIV infection, pregnancy tests, detection of proteins, etc. The ELISA market is expected to show robust growth during the forecast period. The growth may be attributed to the rising incidence of infectious and chronic diseases, which require ELISA as a cost-effective diagnostic tool. However, stringent regulatory requirements, as well as unfavorable reimbursement policies about ELISA, might hamper the market growth during the given time frame.

Market Drivers:

• The rising prevalence of infectious diseases is predicted to propel the market growth.

One of the key drivers fuelling the market's expansion is the rising prevalence of infectious diseases like HIV, Hepatitis, malaria, dengue, and influenza, among other ailments. At the end of 2021, the WHO estimated that there were 38.4 million HIV-positive individuals worldwide, with more than two-thirds of them living in Africa. The WHO also claimed that dengue fever was among the top ten health threats facing the world. Over the past 50 years, dengue incidences have increased by about 3000% worldwide. WHO also estimated that more than 296 million individuals worldwide have hepatitis B infection as of 2019.

The demand for diagnosis is anticipated to rise as a result of the rising occurrence of infectious diseases. The market is anticipated to expand due to the rising use of cutting-edge diagnostic techniques for screening these disorders, such as enzyme-linked immunosorbent tests.

Additionally, the growing geriatric population, which is globally at risk of contracting illnesses and chronic diseases and requires routine diagnosis, is anticipated to fuel market expansion. In comparison to younger individuals, potentially dangerous illnesses are more likely in elderly patients, according to the NCBI (National Center for Biotechnology Information), which published this information in 2021. Thus, it is anticipated that these factors will considerably raise the market's growth by boosting demand for enzyme-linked immunosorbent assays.

• The disease diagnosis segment is anticipated to surge the market growth.

Due to the growing use of enzyme-linked immunosorbent assay tests for the diagnosis of specific antigens, a sizable share of the disease diagnosis market has been predicted. In 2022, the WHO estimated that non-communicable illnesses caused around 41 million deaths each year, equivalent to 71% of all deaths worldwide. Due to these occurrences, there is now a greater need for efficient diagnostic techniques like ELISA for prompt detection to minimize death occurrences.

Additionally, according to the Global Cancer Observatory, there were approximately 19.3 million new cases of cancer and nearly 10.0 million cancer deaths worldwide in 2020. As ELISA is a useful instrument for assessing antigens, the rise in cancer incidence around the world is driving up demand for it.

The Enzyme-Linked Immunosorbent Assay can be used to find both breast cancer antigens and prostate cancer antigens, according to a 2020 Nature Scientific study. Such accurate antigen screening and cost-effective diagnosis are anticipated to boost ELISA demand and drive the market's expansion during the analyzed period.

North America is Expected to Hold a Significant Share in the Market

Because of the rapid development of technological breakthroughs in screening instruments like ELISA, the US is likely to dominate the global market. The increasing incidences of multiple infectious and chronic diseases in this demography are contributing to the strong demand for Enzyme-Linked Immunosorbent Assay. For instance, the CDC (Centre for Ailment Control and Prevention) reported in 2022 that over 60% of Americans had at least one chronic disease, such as cancer, cardiovascular disease, or stroke.

The market in this region is anticipated to grow as a result of rising R&D expenditures as well as numerous funding initiatives for diagnostics. Listed firms on the biotechnology index expanded their R&D spending by about 16% on average in 2020 to USD 284.25 million in the US, based on the Binder Dijker Otte USA Reports from 2020.

Additionally, in 2021, the Department of Health and Human Services said that it would deploy USD 650 million from the American rescue plan to increase production capabilities for swift, high-quality diagnostic tests. Therefore, it is projected that all of these aspects will support the North American regional market well over the predicted period.

Key Developments:

• September 2022- Neogen Corporation introduced its Veratox VIP assay for cashew detection, the second in its enhanced quantitative ELISA line. This innovative test offers robust performance across sample types and maintains the simple testing methodology of the Veratox product line. Neogen aims to offer highly sensitive tests that can detect even the lowest levels of food allergens, protecting consumers worldwide. The test demonstrates a high level of specificity to very low levels of cashew protein, down to 0.2 ppm. The Veratox VIP for Cashew uses the same testing methodology as its existing Veratox product line, including a 30-minute time-to-result and ready-to-use, non-hazardous reagents.
• September 2022- J Mitra introduced the HCV Gen 4 Ag & Ab Microlisa, a 4th Generation Elisa-based HCV test. This in-vitro qualitative ELISA detects HCV core antigens and antibodies against HCV in human serum or plasma. The test is designed to help detect chronic HCV infections early, reducing the window period for acute infection by 5-7 weeks compared to the 3rd generation test. The test is particularly useful in high-risk groups and HIV/HCV co-infected patients. The Elisa test offers higher sensitivity and specificity, and batch processing can result in a quick turnaround time. J Mitra has played a significant role in improving HCV diagnosis in India.

Segmentation:

• By Type
  • Indirect ELISA
  • Sandwich ELISA
  • Competitive ELISA
• By Application
  • Food and Beverage
  • Vaccine Development
  • Immunology
  • Diagnosis
  • Drug Monitoring
  • Others 
• By End Users
  • Pharmaceutical Industries
  • Hospitals and Clinics
  • Diagnostic Centres
  • Others 
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Others
  • Middle East and Africa (MEA)
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Taiwan
    • Others